Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation

International Journal of Cancer

Volumn 135, Issue 2, 2014, Pages 308-318

  Shinjo, Kanako ^a   Yamashita, Yoriko ^a,b   Yamamoto, Eiko ^a   Akatsuka, Shinya ^a   Uno, Nozomi ^a   Kamiya, Akihiro ^b   Niimi, Kaoru ^a   Sakaguchi, Yuka ^a   Nagasaka, Tetsuro ^a   Takahashi, Takashi ^a   Shibata, Kiyosumi ^a   Kajiyama, Hiroaki ^a   Kikkawa, Fumitaka ^a   Toyokuni, Shinya ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

chromobox homolog 7 (CBX7); expression microarray; immunohistochemistry; ovarian clear cell adenocarcinoma; siRNA; TNFSF10 (TRAIL)

Indexed keywords

ANRIL; CHROMOBOX 7; LONG UNTRANSLATED RNA; POLYCOMB GROUP PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CBX7 GENE; CELL VIABILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OVARIAN CLEAR CELL ADENOCARCINOMA; OVARY ADENOCARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER CELL LINE; REGULATORY MECHANISM; SURVIVAL RATE; TRAIL GENE;

CHROMOBOX HOMOLOG 7 (CBX7); EXPRESSION MICROARRAY; IMMUNOHISTOCHEMISTRY; OVARIAN CLEAR CELL ADENOCARCINOMA; SIRNA; TNFSF10 (TRAIL);

ADENOCARCINOMA, CLEAR CELL; APOPTOSIS; BLOTTING, WESTERN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; IN SITU NICK-END LABELING; KAPLAN-MEIER ESTIMATE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 1; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84899998613     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28692     Document Type: Article

References (34)

1. Japanese Gynecological Committee. Annual report on Japanese gynecologic cancer of 2010. Acta Obstet Gynaecol Jpn 2012: 1071.
2. Del Carmen MG, Birrer M, Schorge JO,. Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol 2012; 126: 481-90.
3. Kennedy AW, Biscotti CV, Hart WR, et al. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989; 32: 342-9.
4. Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012; 13: 385-94.
5. Yamaguchi K, Mandai M, Toyokuni S, et al. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res 2008; 14: 32-40.
6. Yamashita Y, Akatsuka S, Shinjo K, et al. Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis. PloS One 2013; 8: e57724.
7. Mackay HJ, Brady MF, Oza AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010; 20: 945-52.
8. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary-a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88: 2584-9.
9. Simon JA, Kingston RE,. Mechanisms of Polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 2009; 10: 697-708.
10. Richly H, Aloia L, Di Croce L,. Roles of the Polycomb group proteins in stem cells and cancer. Cell Death Dis 2011; 2: e204.
11. Gil J, Bernard D, Martinez D, et al. Polycomb CBX7 has a unifying role in cellular lifespan. Nat Cell Biol 2004; 6: 67-72.
12. Bernard D, Martinez-Leal JF, Rizzo S, et al. CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene 2005; 24: 5543-51.
13. Scott CL, Gil J, Hernando E, et al. Role of the chromobox protein CBX7 in lymphomagenesis. Proc Nat Acad Sci USA 2007; 104: 5389-94.
14. Zhang X-W, Zhang L, Qin W, et al. Oncogenic role of the chromobox protein CBX7 in gastric cancer. J Exp Clin Cancer Res 2010; 29: 114.
15. Yap KL, Li S, Munoz-Cabello AM, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by Polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 2010; 38: 662-74.
16. Uno S, Zembutsu H, Hirasawa A, et al. A genome-wide association study identifies genetic variants in the CDKN2BAS locus associated with endometriosis in Japanese. Nat Genet 2010; 42: U70-U88.
17. Karamitopoulou E, Pallante P, Zlobec I, et al. Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. Eur J Cancer 2010; 46: 1438-44.
18. Pallante P, Federico A, Berlingieri MT, et al. Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res 2008; 68: 6770-8.
19. Forzati F, Federico A, Pallante P, et al. Tumor suppressor activity of CBX7 in lung carcinogenesis. Cell Cycle 2012; 11: 1888-91.
20. Federico A, Pallante P, Bianco M, et al. Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. Cancer Res 2009; 69: 7079-87.
21. Forzati F, Federico A, Pallante P, et al. CBX7 is a tumor suppressor in mice and humans. J Clin Invest 2012; 122: 612-23.
22. Krenke BE, Tereba A, Anderson SJ, et al. Validation of a 16-locus fluorescent multiplex system. J Forensic Sci 2002; 47: 773-85.
23. Kobayashi H, Yamashita Y, Iwase A, et al. The ferroimmunomodulatory role of ectopic endometriotic stromal cells in ovarian endometriosis. Fertil Steril 2012; 98: 415-22.
24. Yamashita Y, Kajiura D, Tang L, et al. XCR1 expression and biased VH gene usage are distinct features of diffuse large B-cell lymphoma initially manifesting in the bone marrow. Am J Clin Pathol 2011; 135: 556-64.
25. Yamashita Y, Tsurumi T, Mori N, et al. Immortalization of Epstein-Barr virus-negative human B lymphocytes with minimal chromosomal instability. Pathol Int 2006; 56: 659-67.
26. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
27. Yamaguchi K, Mandai M, Oura T, et al. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 29: 1741-52.
28. Toyokuni S,. Molecular mechanisms of oxidative stress-induced carcinogenesis: from epidemiology to oxygenomics. IUBMB life 2008; 60: 441-7.
29. Akatsuka S, Yamashita Y, Ohara H, et al. Fenton reaction induced cancer in wild type rats recapitulates genomic alterations observed in human cancer. PloS One 2012; 7: e43403.
30. Xu K, Wu ZJ, Groner AC, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 2012; 338: 1465-9.
31. Pallante P, Terracciano L, Carafa V, et al. The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. Eur J Cancer 2010; 46: 2304-13.
32. Allen JE, El-Deiry WS,. Regulation of the human TRAIL gene. Cancer Biol Ther 13: 1143-51.
33. Johnstone RW, Frew AJ, Smyth MJ,. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008; 8: 782-98.
34. Dimberg LY, Anderson CK, Camidge R, et al. On the TRAIL to successful cancer therapy?. Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 2012; 32: 1341-50.